Postpartum Depression Treatment Market Size in the 7MM was estimated to be USD 260 million in 2023, and is expected to increase a significant CAGR by 2034, estimates DelveInsight
DelveInsight's 'Postpartum Depression Treatment Market Insights, Epidemiology, and Market Forecast – 2034' report delivers an in-depth understanding of all Postpartum Depression types, historical and forecasted epidemiology as well as the Postpartum Depression market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
Discover which therapies are expected to grab the Postpartum Depression Market Share @ Postpartum Depression Market Outlook
Key Takeaways from the Postpartum Depression Market Report
In May 2025, Nanjing Minova Pharmaceutical Co., Ltd. announced a study is a multicenter, randomized, double-blind, placebo-controlled trial. It includes three groups. Each group will enroll 24 participants. The trial aims todetermine： To evaluate the efficacy of MI078 capsules in treating postpartum depression and to explore the optimal dosing regimen for MI078 capsules.
In May 2025, Reunion Neuroscience Inc. announced a study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo.
In the seven major Postpartum Depression Therapeutics Market, SNRI's and SSRI's constituted 20% market share of the overall Postpartum Depression Drugs Market, while Atypical antidepressants and Antipsychotics held 19% market share, in 2023.
In the 7MM, ZURZUVAE is expected to garner Postpartum Depression Therapeutics market revenue of ~USD 600 million by 2034.
Among the seven major market, the United States held the highest Postpartum Depression Drugs Market Share (64%) of the overall Postpartum Depression market.
Among EU4 and the UK, the UK accounted for the highest Postpartum Depression Treatment Market Size was ~USD 25 million in 2023
Japan accounted for a Postpartum Depression Market Size of ~USD 20 million in 2023, which is expected to increase at a moderate rate by 2034.
The leading Postpartum Depression Companies such as Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited and others.
Promising Postpartum Depression Pipeline Therapies such as SAGE-217, Brexanolone, Aripiprazole, Escitalopram, ZULRESSO®, BRII-296, Ganaxolone, Sertraline and others.
Stay ahead in the Postpartum Depression Therapeutics Market with DelveInsight's Strategic Report @ Postpartum Depression Treatment Market
Postpartum Depression Epidemiology
Total Diagnosed Prevalent Population of Maternal Postpartum Depression
Download the report to understand which factors are driving Postpartum Depression Epidemiology trends @ Postpartum Depression Prevalence
Postpartum Depression Marketed Therapies
ZURZUVAE (zuranolone) : Sage Therapeutics/Biogen
Zuranolone (SAGE-217) is an investigational, oral, novel medicine in development for postpartum depression (PPD). It is given once daily, a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders, including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain, and the central nervous system (CNS) significantly regulates CNS function. SAGE-217 has been optimized for selectivity to synaptic and extrasynaptic type a γ-aminobutyric acid (GABAA) receptors and a pharmacokinetic profile for daily oral dosing.
ZULRESSO: Sage Therapeutics
ZULRESSO is a proprietary IV formulation of brexanolone. Brexanolone is chemically identical to allopregnanolone, a naturally occurring neuroactive steroid that acts as a positive allosteric modulator of gamma-aminobutyric acid (GABA) receptors indicated for treating PPD in adults. Brexanolone is available to patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility. In addition, patients must be monitored continuously during the drug infusion due to the risk of serious side effects. Notably, ZULRESSO (brexanolone) is the first drug approved by the US FDA specifically for PPD in adults.
Postpartum Depression Emerging Therapies
Ganaxolone: Marinus Pharmaceuticals
Ganaxolone (CCD-1042) is a lead clinical-stage drug candidate that brings a GABAA receptor modulating mechanism and an extensive safety database with exhibited anti-epileptic (antiseizure), anxiolytic (anti-anxiety) and anti-depressive activity in development by Marinus Pharmaceuticals. It is being developed in three different dosage forms (IV, capsule, and liquid) to maximize therapeutic reach to adult and pediatric patients in acute and chronic care settings with severe PPD. Unlike benzodiazepines, ganaxolone exhibits antiseizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors. Ganaxolone has been designed with an added methyl group that prevents back conversion to an active steroid, which unlocks ganaxolone's potential for chronic use. In preclinical studies, ganaxolone exhibited potency and efficacy comparable to allopregnanolone.
To learn more about Postpartum Depression Treatment guidelines, visit @ Postpartum Depression Clinical Trials Assessment
Postpartum Depression Market Outlook
Antidepressants, such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR (Fluvoxamine Maleate), and Paxil CR (paroxetine) form the mainstay in the Postpartum Depression treatment. Although these drugs are approved for treating depression-related disorders such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), treatment-resistant depression (TRD), etc., they are being used as off-label drugs for the treatment of PPD. The type of medication prescribed by the doctors largely depends on the set of symptoms, severity and the specific type of PPD the patient is suffering from. The primary concern about antidepressants is the uncertainty in the outcomes and their side effects on new born due to breastfeeding. Though antidepressants are not necessarily a permanent cure for PPD, they are an important aspect of managing depression symptoms and restoring quality of life.
Postpartum Depression Treatment Landscape
Antidepressant medications, cognitive-behavioral therapy (CBT), and interpersonal therapy are effective in treating Postpartum Depression. Other Postpartum Depression treatments which may be useful include psychodynamic therapy, light therapy, exercise, and yoga, but the current research evidence about the efficacy of such treatment regimens is more preliminary.
Scope of the Postpartum Depression Market Report
Coverage- 7MM
Study Period- 2020-2034
Postpartum Depression Companies- Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited and others.
Postpartum Depression Pipeline Therapies- SAGE-217, Brexanolone, Aripiprazole, Escitalopram, ZULRESSO®, BRII-296, Ganaxolone, Sertraline and others.
Postpartum Depression Market Dynamics: Postpartum Depression Market Drivers and Barriers
Postpartum Depression Market Access and Reimbursement, Unmet Needs and Future Perspectives
Table of Content
1. Key Insights
2. Report Introduction
3. Postpartum Depression Market Overview at a Glance
4 Executive Summary of Postpartum Depression
5 Key events
6 Disease Background and Overview
7 Treatment and Management
8 Methodology
9 Epidemiology and Patient Population
10 Patient Journey
11 Marketed Therapies
12 Emerging Therapies
13 Postpartum Depression (PPD): Seven Major Market Analysis
14 KOL Views
15 SWOT Analysis
16 Unmet Needs
17 Market Access and Reimbursement
18 Appendix
19 DelveInsight Capabilities
20 Disclaimer
21 About DelveInsight
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/postpartum-depression-ppd-market
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
MASH Market Size in the 7MM was ~USD 1.8 billion in 2023, is projected to grow at a CAGR of 24%, estimates DelveInsight
DelveInsight's ' MASH Treatment Market Insights, Epidemiology, and Market Forecast – 2034 ' report delivers an in-depth understanding of MASH, historical and forecasted epidemiology, as well as the MASH market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. Discover which therapies are expected to grab the MASH Market Share @ MASH Market Outlook Key Takeaways from the MASH Market Report In June 2025, Akero Therapeutics Inc. announced a study is to assess the safety and tolerability of EFX compared to placebo in subjects with non-invasively diagnosed NASH/MASH and NAFLD/MASLD. In June 2025, Boehringer Ingelheim conducted a study is to find out whether a medicine called survodutide helps people with MASH and moderate or advanced liver fibrosis improve their liver function. This study is to find out the effect of survodutide on MASH and liver fibrosis. In June 2025, 89bio Inc. organized a study will assess the efficacy and safety of pegozafermin administered in participants with compensated cirrhosis due to MASH (biopsy-confirmed fibrosis stage F4 MASH [previously known as nonalcoholic steatohepatitis, NASH]). According to DelveInsight's estimates, there were ~215 million prevalent cases of MASLD (formerly known as NAFLD) in the 7MM in 2023, including ~30 million prevalent cases of MASH. Of the total MASH cases, ~8 million were diagnosed in the 7MM. Among the 7MM, the US had the highest number of MASH Diagnosed Prevalent Cases, with ~4 million cases in 2023, a figure projected to increase by 2034. In 2023, EU4 and the UK accounted for ~3 million MASH diagnosed prevalent cases with Germany having the highest at ~780 thousand cases, followed by Italy with ~615 thousand cases. In contrast, Spain had the least, with ~340 thousand cases. In 2023, the UK had ~480 thousand MASH Diagnosed Prevalent Cases. In 2023, Japan recorded ~670 thousand MASH diagnosed prevalent cases, a number expected to rise by 2034. In 2023, the US had the following severity-specific diagnosed prevalent cases of MASH: ~880 thousand cases at the F0 stage, ~1,610 thousand at the F1 stage, ~880 thousand at the F2 stage, ~510 thousand at the F3 stage, and ~340 thousand at the F4 stage. The leading MASH Companies such as 89bio, Inc., Akero Therapeutics, Galectin Therapeutics, Viking Therapeutics, Novo Nordisk A/S, Inventiva, and others. Promising MASH Pipeline Therapies such as TVB-2640, Survodutide, Miricorilant (Cohort B), Efimosfermin, Pegozafermin, DD01, ALG-055009, and others. Stay ahead in the MASH Therapeutics Market with DelveInsight's Strategic Report @ MASH Treatment Market MASH Epidemiology Segmentation in the 7MM Total MASH Prevalent Cases Total MASH Prevalent Cases Total Diagnosed Prevalent Cases MASH Severity-specific Diagnosed Prevalent Cases Download the report to understand which factors are driving MASH Epidemiology trends @ MASH Prevalence MASH Marketed Drugs REZDIFFRA (resmetirom): Madrigal Pharmaceuticals REZDIFFRA (resmetirom), a Thyroid Hormone Receptor-beta (THR-ß) agonist, is approved for treating adults with noncirrhotic MASH and moderate to advanced liver fibrosis (F2-F3), in conjunction with diet and exercise. It received accelerated approval due to improvements in MASH and fibrosis. In March 2024, the US FDA approved REZDIFFRA for adults with noncirrhotic MASH with moderate to advanced liver fibrosis (F2 to F3). MASH Emerging Drugs Efruxifermin (EFX): Akero Therapeutics Efruxifermin (EFX), Akero Therapeutics' leading candidate for MASH, is an engineered Fc-FGF21 fusion protein mimicking the biological activity of native FGF21. EFX has shown promise in reducing liver fat, inflammation, and fibrosis, while enhancing insulin sensitivity and lipid metabolism. It offers once-weekly dosing and a favorable tolerability profile in clinical trials. Currently, EFX is being evaluated in three Phase III studies, with encouraging results from Phase II trials showing its potential to reverse fibrosis and improve liver function. The Phase III SYNCHRONY study is expected to provide results in 2026. VK2809 (TRß Agonist): Viking Therapeutics VK2809 is an orally available, liver-targeted agonist of the Thyroid Hormone Beta Receptor (TRß), designed to specifically modulate lipid metabolism. By selectively activating TRß in liver tissue, VK2809 aims to improve cholesterol and lipoprotein levels through the upregulation of genes involved in lipid clearance. The compound has shown significant therapeutic potential in lipid disorders, meeting both primary and secondary endpoints in the Phase IIb VOYAGE study for patients with NASH/MASH and fibrosis, as well as in a Phase IIa study for patients with elevated LDL-C and MASLD. Efimosfermin alfa (formerly BOS-580): Boston Pharmaceuticals Efimosfermin alfa (BOS-580), developed by Boston Pharmaceuticals, is a long-acting variant of FGF21 designed to regulate metabolic pathways, reducing liver fat, inflammation, and fibrosis in MASH patients. Manufactured in mammalian cells for human-like glycosylation, it is administered as a once-monthly subcutaneous injection. BOS-580 is currently undergoing Phase II trials for MASH treatment. In September 2020, Boston Pharmaceuticals licensed the genetically engineered FGF21 variant from Novartis, positioning it as a potential best-in-class treatment for MASH. To learn more about MASH Treatment guidelines, visit @ MASH Clinical Trials Assessment MASH Companies 89bio, Inc., Akero Therapeutics, Galectin Therapeutics, Viking Therapeutics, Novo Nordisk A/S, Inventiva, and others. MASH Drugs Market Insights Efruxifermin (EFX) is an investigational Fc-FGF21 fusion protein developed by Akero Therapeutics for the treatment of MASH. Designed to mimic the biological activity of FGF21, EFX aims to address key drivers of MASH by reducing liver fat and inflammation, reversing fibrosis, and improving insulin sensitivity and lipid metabolism. In a 96-week Phase IIb study, 39% of patients with compensated cirrhosis due to MASH experienced a reversal of cirrhosis without worsening of the disease, compared to 15% in the placebo group. These promising results have led to the initiation of the Phase III SYNCHRONY clinical program, which includes trials evaluating EFX in patients with pre-cirrhotic MASH (F2-F3 fibrosis) and those with compensated cirrhosis (F4) due to MASH. MASH Treatment Market The MASH treatment landscape is rapidly evolving, particularly with the USFDA's accelerated approval of Madrigal's REZDIFFRA, now considered a key therapy for patients with moderate to advanced liver fibrosis. This selective thyroid hormone receptor-beta agonist has shifted the approach from invasive liver biopsies to non-invasive diagnostic methods, improving patient access to treatment. The landscape is further shaped by a diverse pipeline of therapies targeting various mechanisms, such as FXR agonists, PPAR modulators, and GLP-1 receptor agonists, with clinical trials exploring combination therapies to address the complex nature of the disease. As researchers focus on personalized medicine and better patient stratification, the priority remains refining treatment strategies while navigating challenges in trial recruitment and regulatory requirements. The combination of emerging therapies and existing lifestyle interventions continues to influence clinical practice in managing MASH/NASH. Scope of the MASH Market Report Coverage- 7MM Study Period- 2020-2034 MASH Companies- 89bio, Inc., Akero Therapeutics, Galectin Therapeutics, Viking Therapeutics, Novo Nordisk A/S, Inventiva, and others. MASH Pipeline Therapies- TVB-2640, Survodutide, Miricorilant (Cohort B), Efimosfermin, Pegozafermin, DD01, ALG-055009, and others. MASH Market Dynamics: MASH Market Drivers and Barriers MASH Market Access and Reimbursement, Unmet Needs and Future Perspectives Table of Contents 1. Key Insights 2. MASH Market Report Introduction 3. MASH Market Overview at a Glance 4. Methodology of Epidemiology and Market 5. Executive Summary 6. Key Events 7. Disease Background and Overview 8. MASH Epidemiology and Patient Population 9. Patient Journey 10. MASH Marketed Drugs 11. MASH Emerging Drugs 12. MASH – 7MM Market Analysis 13. Key Opinion Leaders' Views 14. MASH Unmet Needs 15. MASH SWOT Analysis 16. MASH Market Access and Reimbursement 17. Appendix 18. DelveInsight Capabilities 19. Disclaimer 20. About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Globe and Mail
3 hours ago
- Globe and Mail
Obesity Drugs Market 2034: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight
"Obesity Drugs Market" Obesity Companies such as Yuhan, Click Therapeutics, Novo Nordisk, ProQR Therapeutics, Bukwang Pharmaceutical, Empros Pharma, Boehringer Ingelhium, Rhythm Pharmaceuticals, BioRestorative Therapies, Hanmi Pharmaceuticals, Carmot Therapeutics, D&D Pharmatech, SCOHIA PHARMA, Nano Precision Medical, Terns Pharmaceuticals, Caliway Biopharmaceutics, Eli Lilly and Company, and others (Albany, USA) DelveInsight's 'Obesity Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of Obesity, historical and forecasted epidemiology as well as the Obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Obesity market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Obesity market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Obesity treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Obesity market. Request for a Free Sample Report @ Obesity Market Forecast Some facts of the Obesity Market Report are: In March 2025, Novo Nordisk launched NovoCare® Pharmacy, a direct-to-patient delivery service, to ensure access to Wegovy® (semaglutide) injection in all dose strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg). This service offers uninsured patients or those with commercial insurance lacking obesity medicine coverage the option to purchase Wegovy® at a reduced cost of $499 per month. This initiative expands Novo Nordisk's efforts to meet the needs of individuals living with obesity, following the FDA's confirmation that the shortage of the medication has been resolved and that all doses now meet or exceed U.S. demand. In February 2025, Eli Lilly launched 7.5 mg and 10 mg Zepbound (tirzepatide) vials for $499 through the Zepbound Self Pay Journey Program, alongside price reductions for 2.5 mg and 5 mg vials. These are available exclusively via LillyDirect Self Pay Pharmacy Solutions, offering direct savings outside of insurance. In February 2025, Amgen announced that the U.S. FDA has placed a hold on a study of the company's early-stage obesity candidate, AMG 513, marking another potential setback in its efforts to enter the growing weight loss drug market. Amgen has provided limited information about the drug, including its mechanism of action. In January 2025, Novo Nordisk reported that a high dose of its obesity drug Wegovy led to greater weight loss than the approved regimen in a Phase III trial. However, the data also suggest that Eli Lilly's rival GLP-1 drug Zepbound may still have an advantage over Wegovy. In January 2025, Verdiva Bio Limited launched as a clinical-stage biopharmaceutical company focused on innovative therapies for obesity and cardiometabolic disorders. The company is advancing next-generation oral and injectable treatments and raised $411M in an oversubscribed Series A round, co-led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital. In January 2025, Eli Lilly filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA. The court has ordered the Outsourcing Facilities Association to respond by January 15, with Eli Lilly's reply due by January 21. As per DelveInsight's estimates, the United States accounted for the highest number of total prevalent cases of Obesity among the 7MM in 2023. DelveInsight's consultant estimates that adult patients constituted the maximum number of cases of obesity patients seeking help in 2023. According to the findings, treatment rate for children was found to be less than that of adults across countries. Among EU4 and the UK, the highest number of treated cases of obesity in adults was observed in the United Kingdom in 2023, which is followed by Germany. The leading Obesity Companies such as Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others Promising Obesity Therapies such as IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others. On June 2023, Eli Lilly and Company (NYSE: LLY) announced the new phase 2 data from retatrutide, Lilly's investigational molecule being studied for the treatment of obesity. At 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) met the primary endpoint for the efficacy estimand in participants living with obesity or overweight without diabetes, demonstrating a mean weight reduction up to 17.5% (41.2 lb. or 18.7 kg). In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% (57.8 lb. or 26.2 kg)ii at the end of the 48-week treatment duration. On June 2023, Pfizer (NYSE: PFE) updated that it is scrapping its once-a-day experimental obesity pill because of concerns about liver safety, but will continue developing its other obesity pill, the twice-daily treatment danuglipron, as it races to rival the success of other weight loss treatments. On May 2023, Novo Nordisk (NYSE: NVO) announced positive results from a phase IIIa study, OASIS 1, in the global OASIS program for a once-daily oral formulation of semaglutide in obesity. Obesity Overview Obesity is a chronic condition characterized by an excessive accumulation of body fat, leading to adverse health effects and increased risk of various diseases. It is typically defined by a body mass index (BMI) of 30 or higher. Obesity results from complex interactions between genetic, environmental, socioeconomic, and behavioral factors. Sedentary lifestyles, high-calorie diets, and genetic predispositions contribute to its development. Obesity is associated with numerous health complications, including type 2 diabetes, cardiovascular disease, hypertension, certain cancers, and musculoskeletal disorders. Additionally, it can impair quality of life and increase mortality rates. Prevention and management strategies for obesity include dietary modifications, regular physical activity, behavioral therapy, medications, and in severe cases, bariatric surgery. Public health initiatives and policies aimed at promoting healthy lifestyles and reducing obesity prevalence are essential to address this global epidemic and its associated health burdens. Learn more about Obesity treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Obesity Market The Obesity market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Obesity market trends by analyzing the impact of current Obesity therapies on the market and unmet needs, and drivers, barriers, and demand for better technology. This segment gives a thorough detail of the Obesity market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Obesity market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Obesity market in 7MM is expected to witness a major change in the study period 2020-2034. Obesity Epidemiology The Obesity epidemiology section provides insights into the historical and current Obesity patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Obesity market report also provides the diagnosed patient pool, trends, and assumptions. Explore more about Obesity Epidemiology @ Obesity Market Dynamics Obesity Drugs Uptake This section focuses on the uptake rate of the potential Obesity drugs recently launched in the Obesity market or expected to be launched in 2020-2034. The analysis covers the Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug. Obesity Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Obesity market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Obesity Pipeline Development Activities The Obesity report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Obesity key players involved in developing targeted therapeutics. Request for a sample report to understand more about the Obesity pipeline development activities @ Obesity Medication and Approved drugs Obesity Therapeutics Assessment Major key companies are working proactively in the Obesity Therapeutics market to develop novel therapies which will drive the Obesity treatment markets in the upcoming years are Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma and others. Learn more about the emerging Obesity therapies & key companies @ Obesity Clinical Trials and Advancements Obesity Report Key Insights 1. Obesity Patient Population 2. Obesity Market Size and Trends 3. Key Cross Competition in the Obesity Market 4. Obesity Market Dynamics (Key Drivers and Barriers) 5. Obesity Market Opportunities 6. Obesity Therapeutic Approaches 7. Obesity Pipeline Analysis 8. Obesity Current Treatment Practices/Algorithm 9. Impact of Emerging Therapies on the Obesity Market Table of Contents 1. Key Insights 2. Executive Summary 3. Obesity Competitive Intelligence Analysis 4. Obesity Market Overview at a Glance 5. Obesity Disease Background and Overview 6. Obesity Patient Journey 7. Obesity Epidemiology and Patient Population 8. Obesity Treatment Algorithm, Current Treatment, and Medical Practices 9. Obesity Unmet Needs 10. Key Endpoints of Obesity Treatment 11. Obesity Marketed Products 12. Obesity Emerging Therapies 13. Obesity Seven Major Market Analysis 14. Attribute Analysis 15. Obesity Market Outlook (7 major markets) 16. Obesity Access and Reimbursement Overview 17. KOL Views on the Obesity Market 18. Obesity Market Drivers 19. Obesity Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer About DelveInsight DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector. Media Contact Company Name:DelveInsight Business Research LLP Contact Person: Ankit Nigam Email:Send Email Phone: +14699457679 Address:304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Obesity Drugs Market 2034: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight
Globe and Mail
5 hours ago
- Globe and Mail
Postpartum Depression Treatment Market Size in the 7MM was estimated to be USD 260 million in 2023, and is expected to increase a significant CAGR by 2034, estimates DelveInsight
DelveInsight's 'Postpartum Depression Treatment Market Insights, Epidemiology, and Market Forecast – 2034' report delivers an in-depth understanding of all Postpartum Depression types, historical and forecasted epidemiology as well as the Postpartum Depression market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan. Discover which therapies are expected to grab the Postpartum Depression Market Share @ Postpartum Depression Market Outlook Key Takeaways from the Postpartum Depression Market Report In May 2025, Nanjing Minova Pharmaceutical Co., Ltd. announced a study is a multicenter, randomized, double-blind, placebo-controlled trial. It includes three groups. Each group will enroll 24 participants. The trial aims todetermine： To evaluate the efficacy of MI078 capsules in treating postpartum depression and to explore the optimal dosing regimen for MI078 capsules. In May 2025, Reunion Neuroscience Inc. announced a study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms in participants with moderate-to-severe postpartum depression (PPD) as compared to active-placebo. In the seven major Postpartum Depression Therapeutics Market, SNRI's and SSRI's constituted 20% market share of the overall Postpartum Depression Drugs Market, while Atypical antidepressants and Antipsychotics held 19% market share, in 2023. In the 7MM, ZURZUVAE is expected to garner Postpartum Depression Therapeutics market revenue of ~USD 600 million by 2034. Among the seven major market, the United States held the highest Postpartum Depression Drugs Market Share (64%) of the overall Postpartum Depression market. Among EU4 and the UK, the UK accounted for the highest Postpartum Depression Treatment Market Size was ~USD 25 million in 2023 Japan accounted for a Postpartum Depression Market Size of ~USD 20 million in 2023, which is expected to increase at a moderate rate by 2034. The leading Postpartum Depression Companies such as Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited and others. Promising Postpartum Depression Pipeline Therapies such as SAGE-217, Brexanolone, Aripiprazole, Escitalopram, ZULRESSO®, BRII-296, Ganaxolone, Sertraline and others. Stay ahead in the Postpartum Depression Therapeutics Market with DelveInsight's Strategic Report @ Postpartum Depression Treatment Market Postpartum Depression Epidemiology Total Diagnosed Prevalent Population of Maternal Postpartum Depression Download the report to understand which factors are driving Postpartum Depression Epidemiology trends @ Postpartum Depression Prevalence Postpartum Depression Marketed Therapies ZURZUVAE (zuranolone) : Sage Therapeutics/Biogen Zuranolone (SAGE-217) is an investigational, oral, novel medicine in development for postpartum depression (PPD). It is given once daily, a 2-week therapy neuroactive steroid (NAS) GABAA receptor positive allosteric modulator (PAM) specifically designed to relieve several depression disorders, including PPD, major depressive disorder (MDD), and treatment-resistant depression. The GABA system is the major inhibitory signaling pathway of the brain, and the central nervous system (CNS) significantly regulates CNS function. SAGE-217 has been optimized for selectivity to synaptic and extrasynaptic type a γ-aminobutyric acid (GABAA) receptors and a pharmacokinetic profile for daily oral dosing. ZULRESSO: Sage Therapeutics ZULRESSO is a proprietary IV formulation of brexanolone. Brexanolone is chemically identical to allopregnanolone, a naturally occurring neuroactive steroid that acts as a positive allosteric modulator of gamma-aminobutyric acid (GABA) receptors indicated for treating PPD in adults. Brexanolone is available to patients only through a Risk Evaluation and Mitigation Strategy (REMS) program and must be administered at a certified healthcare facility. In addition, patients must be monitored continuously during the drug infusion due to the risk of serious side effects. Notably, ZULRESSO (brexanolone) is the first drug approved by the US FDA specifically for PPD in adults. Postpartum Depression Emerging Therapies Ganaxolone: Marinus Pharmaceuticals Ganaxolone (CCD-1042) is a lead clinical-stage drug candidate that brings a GABAA receptor modulating mechanism and an extensive safety database with exhibited anti-epileptic (antiseizure), anxiolytic (anti-anxiety) and anti-depressive activity in development by Marinus Pharmaceuticals. It is being developed in three different dosage forms (IV, capsule, and liquid) to maximize therapeutic reach to adult and pediatric patients in acute and chronic care settings with severe PPD. Unlike benzodiazepines, ganaxolone exhibits antiseizure and anti-anxiety activity via its effects on synaptic and extrasynaptic GABAA receptors. Ganaxolone has been designed with an added methyl group that prevents back conversion to an active steroid, which unlocks ganaxolone's potential for chronic use. In preclinical studies, ganaxolone exhibited potency and efficacy comparable to allopregnanolone. To learn more about Postpartum Depression Treatment guidelines, visit @ Postpartum Depression Clinical Trials Assessment Postpartum Depression Market Outlook Antidepressants, such as Abilify (aripiprazole), Zoloft (sertraline hydrochloride), Spravato (esketamine), Prozac (fluoxetine capsules), Celexa (citalopram hydrobromide), Luvox CR (Fluvoxamine Maleate), and Paxil CR (paroxetine) form the mainstay in the Postpartum Depression treatment. Although these drugs are approved for treating depression-related disorders such as major depressive disorder (MDD), obsessive-compulsive disorder (OCD), post-traumatic stress disorder (PTSD), treatment-resistant depression (TRD), etc., they are being used as off-label drugs for the treatment of PPD. The type of medication prescribed by the doctors largely depends on the set of symptoms, severity and the specific type of PPD the patient is suffering from. The primary concern about antidepressants is the uncertainty in the outcomes and their side effects on new born due to breastfeeding. Though antidepressants are not necessarily a permanent cure for PPD, they are an important aspect of managing depression symptoms and restoring quality of life. Postpartum Depression Treatment Landscape Antidepressant medications, cognitive-behavioral therapy (CBT), and interpersonal therapy are effective in treating Postpartum Depression. Other Postpartum Depression treatments which may be useful include psychodynamic therapy, light therapy, exercise, and yoga, but the current research evidence about the efficacy of such treatment regimens is more preliminary. Scope of the Postpartum Depression Market Report Coverage- 7MM Study Period- 2020-2034 Postpartum Depression Companies- Sage Therapeutics, Biogen, Marinus Pharmaceuticals, Lipocine, Brii Biosciences Limited and others. Postpartum Depression Pipeline Therapies- SAGE-217, Brexanolone, Aripiprazole, Escitalopram, ZULRESSO®, BRII-296, Ganaxolone, Sertraline and others. Postpartum Depression Market Dynamics: Postpartum Depression Market Drivers and Barriers Postpartum Depression Market Access and Reimbursement, Unmet Needs and Future Perspectives Table of Content 1. Key Insights 2. Report Introduction 3. Postpartum Depression Market Overview at a Glance 4 Executive Summary of Postpartum Depression 5 Key events 6 Disease Background and Overview 7 Treatment and Management 8 Methodology 9 Epidemiology and Patient Population 10 Patient Journey 11 Marketed Therapies 12 Emerging Therapies 13 Postpartum Depression (PPD): Seven Major Market Analysis 14 KOL Views 15 SWOT Analysis 16 Unmet Needs 17 Market Access and Reimbursement 18 Appendix 19 DelveInsight Capabilities 20 Disclaimer 21 About DelveInsight About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
